ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
1.450
+0.040 (2.84%)
At close: Dec 19, 2025, 4:00 PM EST
1.360
-0.090 (-6.21%)
After-hours: Dec 19, 2025, 5:56 PM EST
ALX Oncology Holdings Employees
ALX Oncology Holdings had 80 employees as of December 31, 2024. The number of employees increased by 8 or 11.11% compared to the previous year.
Employees
80
Change (1Y)
8
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,350,125
Market Cap
78.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80 | 8 | 11.11% |
| Dec 31, 2023 | 72 | 14 | 24.14% |
| Dec 31, 2022 | 58 | 15 | 34.88% |
| Dec 31, 2021 | 43 | 20 | 86.96% |
| Dec 31, 2020 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALXO News
- 13 days ago - ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - GlobeNewsWire
- 4 weeks ago - ALX Oncology to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting - GlobeNewsWire
- 2 months ago - ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - GlobeNewsWire
- 2 months ago - ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 3 months ago - ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer - GlobeNewsWire